Free Trial

MetaVia (MTVA) Competitors

MetaVia logo
$0.71 -0.03 (-4.29%)
As of 07/25/2025 03:30 PM Eastern

MTVA vs. VTVT, AVTX, NRXP, ALGS, INMB, CELU, IPSC, SNTI, ZIVO, and JSPR

Should you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include vTv Therapeutics (VTVT), Avalo Therapeutics (AVTX), NRx Pharmaceuticals (NRXP), Aligos Therapeutics (ALGS), INmune Bio (INMB), Celularity (CELU), Century Therapeutics (IPSC), Senti Biosciences (SNTI), ZIVO Bioscience (ZIVO), and Jasper Therapeutics (JSPR). These companies are all part of the "pharmaceutical products" industry.

MetaVia vs. Its Competitors

MetaVia (NASDAQ:MTVA) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

MetaVia has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. Comparatively, vTv Therapeutics has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500.

In the previous week, vTv Therapeutics had 1 more articles in the media than MetaVia. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for MetaVia. MetaVia's average media sentiment score of 1.89 beat vTv Therapeutics' score of 1.28 indicating that MetaVia is being referred to more favorably in the media.

Company Overall Sentiment
MetaVia Very Positive
vTv Therapeutics Positive

vTv Therapeutics' return on equity of -121.46% beat MetaVia's return on equity.

Company Net Margins Return on Equity Return on Assets
MetaViaN/A -222.13% -123.85%
vTv Therapeutics N/A -121.46%-46.75%

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 4.2% of vTv Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

vTv Therapeutics has higher revenue and earnings than MetaVia.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetaViaN/AN/A-$27.59MN/AN/A
vTv Therapeutics$1.02M48.26-$18.46M-$3.01-5.13

MetaVia presently has a consensus target price of $7.50, suggesting a potential upside of 963.68%. vTv Therapeutics has a consensus target price of $35.50, suggesting a potential upside of 130.07%. Given MetaVia's higher possible upside, analysts clearly believe MetaVia is more favorable than vTv Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MetaVia
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
vTv Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

vTv Therapeutics beats MetaVia on 8 of the 10 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTVA vs. The Competition

MetricMetaViaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$14.43M$3.05B$5.69B$9.50B
Dividend YieldN/A2.37%4.58%4.01%
P/E RatioN/A21.1828.2320.08
Price / SalesN/A282.17430.5089.23
Price / CashN/A42.7636.2258.56
Price / Book0.778.378.665.88
Net Income-$27.59M-$55.19M$3.25B$258.72M
7 Day Performance4.63%5.86%4.24%3.72%
1 Month Performance3.69%17.29%10.51%11.73%
1 Year PerformanceN/A4.39%34.43%18.02%

MetaVia Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTVA
MetaVia
2.2605 of 5 stars
$0.71
-4.3%
$7.50
+963.7%
N/A$14.43MN/A0.008
VTVT
vTv Therapeutics
1.54 of 5 stars
$16.68
-1.2%
$35.50
+112.9%
-26.6%$53.28M$17K-5.549News Coverage
Positive News
AVTX
Avalo Therapeutics
3.3406 of 5 stars
$4.90
+2.0%
$30.00
+512.9%
-42.5%$52.80M$440K0.0040News Coverage
Positive News
NRXP
NRx Pharmaceuticals
2.5358 of 5 stars
$3.03
-2.7%
$28.50
+842.1%
+28.2%$52.48MN/A-1.512
ALGS
Aligos Therapeutics
4.306 of 5 stars
$8.53
+0.4%
$70.00
+720.6%
-32.4%$52.12M$3.94M-0.4990News Coverage
Positive News
INMB
INmune Bio
1.9985 of 5 stars
$2.18
+5.1%
$18.40
+746.0%
-68.0%$51.29M$10K-1.1310Positive News
Upcoming Earnings
CELU
Celularity
0.1409 of 5 stars
$2.17
-12.6%
N/A-1.0%$51.11M$54.22M-0.81220News Coverage
Upcoming Earnings
IPSC
Century Therapeutics
3.541 of 5 stars
$0.59
+2.4%
$4.20
+609.5%
-73.7%$51.01M$6.59M-2.04170Positive News
SNTI
Senti Biosciences
2.2678 of 5 stars
$1.95
+3.7%
$8.50
+335.9%
-16.8%$50.86M$2.56M-0.184
ZIVO
ZIVO Bioscience
N/A$13.28
-1.6%
N/A+30.2%$50.69M$15.85K-2.7210
JSPR
Jasper Therapeutics
3.7406 of 5 stars
$3.36
+1.4%
$29.75
+786.7%
-85.2%$50.09MN/A-0.6420

Related Companies and Tools


This page (NASDAQ:MTVA) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners